Alterity Therapeutics Limited (ATHE) News
Follow Alterity Therapeutics Limited (ATHE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
ATHE - Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
ATHE - Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
EQUITY | Sep 03, 2026, 11:05 AM UTC
M
ATHE Granted New US Patent
Alterity Therapeutics announces granting of new US composition of matter patent for ATH434
EQUITY | Aug 12, 2026, 11:05 AM UTC
M
ATHE Releases Q4 FY26 Quarterly Cash Flow Report
ATHE reports Q4 FY26 cash flow
EQUITY | Jul 30, 2026, 11:25 AM UTC
L
Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy
() -- Alterity Therapeutics (ATHE) said Tuesday the US Food and Drug Administration's end-of-phase 2 meeting minutes confirmed agreement on the key elements of the registrational phase 3 trial for ATH434 in multiple syst
REGULATION | Jul 07, 2026, 11:45 AM UTC
L
Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434
Alterity Therapeutics announced that it has received the official meeting minutes from its End-of Phase-2 meeting for ATH434 in Multiple System Atrophy from the FDA. The minutes confirm the elements of the registrational
REGULATION | Jul 07, 2026, 11:32 AM UTC
L
Alterity Therapeutics shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a $16 pr
Alterity Therapeutics shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a $16 price target.
EQUITY | Jun 30, 2026, 05:45 PM UTC
L
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16
Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ: ATHE ) with a Buy rating and announces Price Target of $16.
EQUITY | Jun 30, 2026, 01:21 PM UTC